多重特異性抗體的全球市場:藥物銷售額，藥價，臨床試驗趨勢(2029年)

Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029

出版日期: 2024年08月01日 | 出版商:

KuicK Research | 英文 1200 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

下一代多特異性抗體市場是生物技術和藥物開發領域令人興奮的前沿領域，為創新和成長提供了重大機會。這些工程蛋白可以同時結合兩個或更多不同的靶點，正在徹底改變治療方法，特別是在癌症領域。該領域正迅速從傳統的雙特異性抗體發展到更複雜的三特異性和四特異性抗體，每種抗體都可以針對多種疾病途徑或對針對癌細胞的免疫反應做出反應，在增強癌細胞免疫反應方面具有獨特的優勢。

目前，雙特異性抗體在下一代已獲批准的多特異性抗體中佔據主導地位，有 13 種產品在全球範圍內獲得監管批准。這項初步成功為更複雜的多特異性抗體鋪平了道路，並凸顯了進一步市場擴張的潛力。這些創新療法的市場在 2023 年達到了一個重要的里程碑，全球銷售額超過 80 億美元。這些令人印象深刻的數字證實了臨床實踐中，特別是腫瘤學中對多特異性抗體的令人印象深刻的功效和安全性、接受度以及不斷增長的需求。

下一代多特異性抗體的主要用途是在癌症治療中，它們已顯示出改善傳統單株抗體療法的能力。例如，用於治療小細胞肺癌的雙特異性 T 細胞接合劑 (BiTE) 可同時與 T 細胞上的 CD3 和腫瘤細胞上的 DLL3 結合，有效殺死癌細胞並使效應細胞緊密結合。這種機制在這種罕見且快速生長的肺癌中顯示出了令人印象深刻的結果。其他活動包括用於瀰漫性大 B 細胞淋巴瘤的 epcolitab 和用於多發性骨髓瘤的 tarketamab，這兩種藥物都利用雙特異性技術來增強抗癌活性。

下一代多特異性抗體的市場機會龐大且多方面。目前核准的 13 種雙特異性抗體還有擴展的空間。隨著更複雜的多特異性抗體的臨床試驗的進展，新的批准將會激增，每一個都有可能解決未滿足的醫療需求或提高現有治療的療效。

本報告提供全球多重特異性抗體市場相關調查，提供市場概要，以及藥物趨勢，臨床試驗趨勢，各地區趨勢，及加入此市場的主要企業的競爭情形等資訊。

Global & Regional Market Analysis
Global Multispecific Antibodies Market Opportunity: > USD 40 Billion
Global Multispecific Antibodies Market Sales In 2023: > USD 8 Billion
Number Of Approved Multispecific Antibodies: 13
Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight
Approved Antibodies Dosage & Pricing Insight
Number Of Multispecific Antibodies: In Clinical Trials: > 900
Comprehensive Insight On All Antibodies In Clinical Trials By Company, Country, Indication, & Phase

The market for next generation multispecific antibodies represents an exciting frontier in biotechnology and pharmaceutical development, offering significant opportunities for innovation and growth. These engineered proteins, capable of binding to two or more different targets simultaneously, are revolutionizing therapeutic approaches, especially in oncology. The field has rapidly evolved from the traditional bispecific antibodies to more complex trispecific and tetraspecific constructs, each offering unique advantages in targeting multiple disease pathways or enhancing immune responses against cancer cells.

Currently, bispecific antibodies dominate the approved next generation multispecific antibodies landscape, with 13 products having received regulatory green light around the globe. This initial success has paved the way for more complex multispecific antibodies, highlighting the potential for further market expansion. The market for these innovative therapies crossed a significant milestone in 2023, surpassing US$ 8 billion in global sales. This impressive figure underscores the growing acceptance and demand for multispecific antibodies in clinical practice, particularly in oncology, where they have shown impressive efficacy and safety profiles.

The primary application of next generation multispecific antibodies has been in cancer treatment where they have demonstrated the ability to improve upon traditional monoclonal antibody therapies. For example, bispecific T-cell engagers (BiTE), like Tarlatamab, used in the treatment of small cell lung cancer, simultaneously bind to CD3 on T cells and DLL3 on tumor cells, effectively bringing cancer cells and effector cells in close proximity. This mechanism has shown impressive results in this rare, fast-growing lung cancer. Other examples include Epcoritamab for diffuse large B-cell lymphoma and Talquetamab for multiple myeloma, both leveraging bispecific technology to enhance anti-cancer activity.

The development of trispecific and tetraspecific antibodies represents the next wave of innovation in the field. These more complex molecules offer the potential to engage multiple proteins or immune cell types simultaneously, potentially leading to more precise and potent therapeutic effects. For example, researchers from the Osaka Metropolitan University and Tokyo University of Agriculture and Technology jointly developed a series of trispecific antibodies to engage T cells and NK cells simultaneously against tumors overexpressing the EGFR receptor, potentially offering a more robust anti-tumor response than bispecific antibodies.

The market opportunity for next-generation multispecific antibodies is substantial and multifaceted. There is room for expansion beyond the current 13 approved bispecific antibodies. As more complex multispecific antibodies progress through clinical trials, we can expect a surge in new approvals, each potentially addressing unmet medical needs or offering improved efficacy over existing therapies.

Moreover, the versatility of multispecific antibodies opens doors to applications beyond oncology. While cancer remains the primary focus, research is underway to apply this technology to autoimmune diseases, infectious diseases and neurological disorders. The diversification of therapeutic areas represents a vast untapped market potential. At present, Hemlibra stands at the forefront of multispecific antibodies developed for non-cancer indications, cementing its place as the highest-selling bispecific antibody in the market for several years consecutively.

The financial trajectory of the multispecific antibody market is highly promising. Having crossed the US$ 8 billion market in 2023, our analysis projects continues robust growth and the market is expected to surpass USD 40 Billion by 2029. Factors driving this growth include the increasing incidence of cancer worldwide, growing acceptance of immunotherapy approaches, and the potential for these therapies to commands premium pricing due to their complex engineering and enhanced efficacy.

In conclusion, the next generation multispecific antibody market presents a compelling opportunity for growth and innovation in the biopharmaceutical industry. With its strong foundation in bispecific antidotes and the emerging potential of tri- and tetraspecific antibodies, this field is poised for significant expansion beyond its currently US$ 8 billion market size. As research progresses and more products receive approved, multispecific antibodies are set to play an increasingly important role in the treatment of cancer and potentially other diseases, offering substantial rewards for companies at the forefront of this technological revolution.

1. Introduction to Next Generation Multispecific Antibodies

2. Multispecific Antibody Current Clinical Development & Future Commercialization Outlook

2.1 Current Market Overview
2.2 Future Commercialization Opportunity

3. Multispecific Antibody Proprietary Technologies by Company

4. Multispecific Antibody Clinical Development & Market Trends by Region

4.1 US
4.2 EU
4.3 China
4.4 UK
4.5 Japan
4.6 Australia
4.7 South Korea
4.8 Canada

5. Multispecific Antibody Clinical Trends by Indication

5.1 Cancer
5.2 Hematological Disorders
5.3 Microbial Infections
5.4 Autoimmune & Inflammatory Disorders
5.5 Ocular Diseases

6. Approved Multispecific Antibodies - Clinical Overview, Pricing & Dosage Insight

6.1 Overview
6.2 Clinical Overview, Pricing & Dosage Insight

7. Approved Multispecific Antibodies - Sales Insight ( 2020 - H1'2024)

8. Global Multispecific Antibodies Clinical Trials Overview (2024 - 2029)

8.1 By Phase
8.2 By Country/Region
8.3 By Company
8.4 By Indication
8.5 By Priority Status
8.6 Patient Segment

9. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III
9.8 Preregistration

10. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication

11. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

11.1 Research
11.2 Preclinical
11.3 Phase I
11.4 Phase I/II

12. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

12.1 Preclinical
12.2 Phase I
12.3 Phase I/II
12.4 Phase II

13. Competitive Landscape

This Chapter Gives Insight On 55 Companies Involved in Clinical Trials Of Multispecific Antibodies

簡介目錄圖表

List of Figures

Figure 2-1: Global -Multispecific Antibodies Sales (US$ Million), 2020-2024
Figure 2-2: Global - Market Sales by Multispecific Antibodies (US$ Million), 2024
Figure 2-3: Global -Market Sales by Multispecific Antibodies (%), 2024
Figure 2-4: Global - Quarterly Sales By Multispecific Antibodies (US$ Million), 2024
Figure 2-5: Global - Quarterly Sales By Multispecific Antibodies (%), 2024
Figure 2-6: US - Quarterly Sales By Multispecific Antibodies (US$ Million), 2024
Figure 2-7: ROW - Quarterly Sales By Multispecific Antibodies (US$ Million), 2024
Figure 2 8: Global - Multispecific Antibodies Market Opportunity Assessment (US$ Billion), 2024 - 2029
Figure 3-1: Grabody I Platform - Mechanism of Action
Figure 3-2: Grabody I Platform - Mechanism of Action
Figure 3-3: Abz2 Bispecific Platform
Figure 3-4: Abz2 Bispecifics - Benefits
Figure 3-5: Neo-X-Prime Bispecific Mechanism
Figure 3-6: BiTE - Structure
Figure 3-7: BiTE Molecule
Figure 3-8: ADAPTIR Bispecific Structure
Figure 3-9: ADAPTIR-FLEX
Figure 3-10: BioAtla CABs - Features
Figure 3-11: BioAtla CABs - Benefits
Figure 3-12: FIT-Ig - Proprietary Bispecific Platform
Figure 3-13: 3-Step DuoBody Production Process
Figure 3-14: DuoHexaBody Molecules - Schematic
Figure 3-15: BEAT Platform - Multispecific Antibodies
Figure 3-16: IMBiologic Bispecific Antibodies - Strategy
Figure 3-17: IMBiologic Bispecific Antibodies - Mechanism of Action
Figure 3-18: ANKET-R Platform - Innate Pharma
Figure 3-19: B-Body Bispecific Antibody - Structre
Figure 3-20: iTAb - Patented Structure
Figure 3-21: iTAb - Mechanism of Action
Figure 3-22: xLinkBsAb - Structure
Figure 3-23: Multiclonics - Distinctive Characteristics
Figure 3-24: Biclonics - Format
Figure 3-25: Merus - Triclonics Platform
Figure 3-26: STEALTH - ModeX Therapeutics
Figure 3-27: MSTAR - ModeX Therapeutics
Figure 3-28: MSTAR - Features
Figure 3-29: DARPin Platform - Molecular Partners
Figure 3-30: Novel HBICE
Figure 3-31: HBICE - Mechanism of Action 1
Figure 3-32: HBICE - Mechanism of Action 2
Figure 3-33: Numab Therapeutics - Technology
Figure 3-34: Phanes Therapeutics - PACbody Platform
Figure 3-35: Phanes Therapeutics - SPECpair Platform
Figure 3-36: Phanes Therapeutics - ATACCbody
Figure 3-37: Purple Biotech - Tribody Antibody Platform
Figure 3-38: PrecisionGATE Bispecific Antibody - Structure
Figure 3-39: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
Figure 3-40: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 3-41: Synimmune - Proprietary Bispecific Antibody Format
Figure 3-42: ALiCE - Characteristics
Figure 3-43: ALiCE - Schematic Diagram & Mechanism of Action
Figure 3-44: BiClone format
Figure 3-45: Zyngenia Technology Approach
Figure 4-1: US - Approved Bispecific Antibodies
Figure 4-2: Chugai Files New Drug Application in Japan for Mosunetuzumab, anti-CD20xCD3 bispecific antibody
Figure 4-3: Chugai Pharmaceutical - Multispecific Antibody Clinical Pipeline
Figure 4-4: SAIL66 Phase I Study (NCT05735366) - Initiation & Completion Year
Figure 4-5: Japan Next Generation Multispecific Antibody Market - Insight
Figure 4-6: Hoffmann La Roche AG Patent (JP2018502835A) - Grant & Expiration Year
Figure 4-7: DR-0201 Phase I Study (NCT06392477) - Initiation & Completion Year
Figure 4-8: Australia - Universities & Research Centers Conducting Next Generation Multispecific Antibody Clinical Trials
Figure 4-9: ABL Bio - Bispecific Antibody Pipeline
Figure 4-10: Multispecific Antibody Combinations
Figure 4-11: CTX-009 (ABL001) Phase I/II Study (NCT04492033) - Initiation & Completion Year
Figure 4-12: Elranatamab Phase II Study (NCT06421675) - Initiation & Completion Year
Figure 4-13: Canada Next Generation Multispecific Antibodies - Key Players
Figure 5-1: Odronextamab (ELM-1) Phase I (NCT02290951) Study - Initiation & Completion Year
Figure 5-2: Odronextamab (ELM-1) Phase II (NCT03888105) Study - Initiation & Completion Year
Figure 5-3: Linvoseltamab (LINKER-MM1) Phase I/II (NCT03761108) Study - Initiation & Completion Year
Figure 5-4: PIT565 Phase I (NCT05397496) Study - Initiation & Completion Year
Figure 5-5: JNJ-79635322 Phase I (NCT05652335) Study - Initiation & Completion Year
Figure 5-6: GNC-038 Phase I/II (NCT05192486) Study - Initiation & Completion Year
Figure 5-7: GNC-038 Phase I/II (NCT05485753) Study - Initiation & Completion Year
Figure 5-8: IPH6501 Phase I/II (NCT06088654) Study - Initiation & Completion Year
Figure 5-9: NM32-2668 Phase I (NCT06299163) Study - Initiation & Completion Year
Figure 5-10: GB263T Phase I/II (NCT05332574) Study - Initiation & Completion Year
Figure 5-11: GNC-039 Phase I (NCT04794972) Study - Initiation & Completion Year
Figure 5-12: Emicizumab Phase II (NCT05345197) Study - Initiation & Completion Year
Figure 5-13: Emicizumab Phase II/III (NCT06155955) Study - Initiation & Completion Year
Figure 5-14: Emicizumab (BCDI-XII) Phase I (NCT05500807) Study - Initiation & Completion Year
Figure 5-15: HMB-001 Phase I/II (NCT06211634) Study - Initiation & Completion Year
Figure 5-16: YBSW015 Early Phase I (NCT05369754) Study - Initiation & Completion Year
Figure 5-17: GR1801 Phase III (NCT05846568) Study - Initiation & Completion Year
Figure 5-18: Imvotamab (IGM-2323-101) Phase I (NCT06041568) Study - Initiation & Completion Year
Figure 5-19: Imvotamab (IGM-2323-102) Phase I (NCT06087406) Study - Initiation & Completion Year
Figure 5-20: PRV-3279 (PREVAIL-2) Phase II (NCT05087628) Study - Initiation & Completion Year
Figure 5-21: DONQ52 (DQB101US) Phase I (NCT05425446) Study - Initiation & Completion Year
Figure 5-22: Mosunetuzumab (GA43191) Phase I (NCT05155345) Study - Initiation & Completion Year
Figure 5-23: Faricimab (MAGIC) Phase II (NCT05681884) Study - Initiation & Completion Year
Figure 5-24: Restoret (EYE103) - Tetravalent, Tri-Specific Antibody Binding Sites
Figure 5-25: EYE103 (AMARONE) Phase I/II Study (NCT05919693) - Initiation & Completion Year
Figure 6-1: Blincyto - Approval Year by Region
Figure 6-2: Blincyto - Patent Filing & Expiration Year
Figure 6-3: Blincyto - Treatment Regimen Cycles (Weeks)
Figure 6-4: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
Figure 6-5: Blincyto - Cost of Single Cycle & Treatment Course for the Treatment of MRD-positive B-cell Precursor ALL
Figure 6-6: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 6-7: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 6-8: Blincyto - Cost of Single Cycle & Treatment Course for Treatment for Relapsed B-Cell Precursor ALL
Figure 6-9: Hemlibra - Approval Years by Region
Figure 6-10: Hemlibra - Cost per Unit & Supply of 30 mg/mL Subcutaneous Injection of Different Volumes (US$), July'2024
Figure 6-11: Hemlibra - Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection of Different Volumes (US$), July'2024
Figure 6-12: Hemlibra - Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/kg/Week)
Figure 6-13: Rybrevant - Price per Unit & Supply of Intravenous Solution (US$), July'2024
Figure 6-14: Rybrevant - Recommended Dose per Cycle by Body Weight (mg)
Figure 6-15: Rybrevant - Dose Reduction in Patients with Weight less than 80 kg (mg)
Figure 6-16: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
Figure 6-17: Vabysmo - First Approval Year by Region
Figure 6-18: Vabysmo - Price per Unit & Supply of Intravitreal Solution (US$), July'2024
Figure 6-19: Lunsumio - Approval Years by Region
Figure 6-20: US - Price per Unit & Supply of Lunsumio Intravenous Solution (US$), July'2024
Figure 6-21: EU - Price per Unit & Supply of Lunsumio Intravenous Solution (US$), July'2024
Figure 6-22: Tecvayli - Approval Years by Region
Figure 6-23: Tecvayli - Patent Acceptance & Expiration Years
Figure 6-24: US - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), July'2024
Figure 6-25: EU - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), July'2024
Figure 6-26: Columvi - Approval Year by Region
Figure 6-27: US - Price per Unit & Supply of Columvi Intravenous Solution (US$), July'2024
Figure 6-28: EU - Price per Unit & Supply of Columvi Intravenous Solution (US$), July'2024
Figure 6-29: Epkinly - Approval Year by Region
Figure 6-30: US - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), July'2024
Figure 6-31: EU - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), July'2024
Figure 6-32: Talvey - Approval Year by Region
Figure 6-33: Talquetamab - FDA & EMA Designation Year
Figure 6-34: Talvey - Patent Acceptance & Expiration Year
Figure 6-35: US - Price per Unit & Supply of Talvey Intravenous Solution (US$), July'2024
Figure 6-36: EU - Price per Unit & Supply of Talvey Intravenous Solution (US$), February'2024
Figure 6-37: Elrexfio - Approval Years by Region
Figure 6-38: Elranatamab - FDA & EMA Designation Year
Figure 6-39: US - Price per Unit & Supply of Elrexfio Subcutaneous Solution (US$), July'2024
Figure 7-1: Global - Annual Blincyto Sales (US$ Million), 2020-2024
Figure 7-2: Global - Quarterly Blincyto Sales (US$ Million), 2024
Figure 7-3: Blincyto - US v/s ROW Sales (US$ Million), H1'2024
Figure 7-4: Global - Blincyto Sales by Region (%), Q1'2024
Figure 7-5: US - Quarterly Blincyto Sales (US$ Million), 2024
Figure 7-6: ROW - Quarterly Blincyto Sales (US$ Million), H1'2024
Figure 7-7: Global - Quarterly Blincyto Sales (US$ Million), 2023
Figure 7-8: US - Quarterly Blincyto Sales (US$ Million), 2023
Figure 7-9: ROW - Quarterly Blincyto Sales (US$ Million), 2023
Figure 7-10: US - Annual Blincyto Sales (US$ Million), 2020-2024
Figure 7-11: ROW - Annual Blincyto Sales (US$ Million), 2019-2023
Figure 7-12: Global - Annual Hemlibra Sales (US$ Million), 2020-2024
Figure 7-13: Regional - US v/s ROW Sales (US$ Million), H1'2024
Figure 7-14: Global - Hemlibra Sales by Region (US$ Million), H1'2024
Figure 7-15: Global - Hemlibra Sales by Region (%), H1'2024
Figure 7-16: US - Annual Hemlibra Sales (US$ Million), 2020-2024
Figure 7-17: Europe - Annual Hemlibra Sales (US$ Million), 2020-2024
Figure 7-18: Japan - Annual Hemlibra Sales (US$ Million), 2020-2024
Figure 7-19: ROW - Hemlibra Sales (US$ Million), 2020-2024
Figure 7-20: Global - Hemlibra Annual Sales by Region (US$ Million), 2023
Figure 7-21: Global - Hemlibra Sales by Region (%), 2023
Figure 7-22: Global - Quarterly Hemlibra Sales (US$ Million), 2023
Figure 7-23: US - Quarterly Hemlibra Sales (US$ Million), 2023
Figure 7-24: Europe - Quarterly Hemlibra Sales (US$ Million), 2023
Figure 7-25: Japan - Quarterly Hemlibra Sales (US$ Million), 2023
Figure 7-26: ROW - Quarterly Hemlibra Sales (US$ Million), 2023
Figure 7-27: Global - Annual Vabysmo Sales (US$ Million), 2022-2024
Figure 7-28: Global - Vabysmo US v/s ROW Sales (US$ Million), H1'2024
Figure 7-29: Global - Vabysmo Sales by Region (US$ Million), H1'2024
Figure 7-30: Global - Vabysmo Annual Sales by Region (%), H1'2024
Figure 7-31: Global - Vabysmo US v/s ROW Sales (US$ Million), 2023
Figure 7-32: Global - Vabysmo Annual Sales by Region (US$ Million), 2023
Figure 7-33: Global - Vabysmo Annual Sales by Region (%), 2023
Figure 7-34: US - Vabysmo Sales (US$ Million), 2022-2024
Figure 7-35: Europe - Vabysmo Sales (US$ Million), 2022-2024
Figure 7-36: Japan - Vabysmo Sales (US$ Million), 2022-2024
Figure 7-37: ROW - Vabysmo Sales (US$ Million), 2022-2024
Figure 7-38: Global - Quarterly Vabysmo Sales (US$ Million), 2023
Figure 7-39: US - Quarterly Vabysmo Sales (US$ Million), 2023
Figure 7-40: Europe - Quarterly Vabysmo Sales (US$ Million), 2023
Figure 7-41: Japan - Quarterly Vabysmo Sales (US$ Million), 2023
Figure 7-42: ROW - Quarterly Vabysmo Sales (US$ Million), 2023
Figure 7-43: Global - Annual Lunsumio Sales (US$ Million), 2022-2024
Figure 7-44: US - Annual Lunsumio Sales (US$ Million), 2022-2024
Figure 7-45: Europe - Annual Lunsumio Sales (US$ Million), 2022-2024
Figure 7-46: Global - Lunsumio Sales by Region (US$ Million), H1'2024
Figure 7-47: Global - Lunsumio Sales by Region (%), H1'2024
Figure 7-48: Global - Lunsumio Annual Sales by Region (US$ Million), 2023
Figure 7-49: Global - Lunsumio Annual Sales by Region (%), 2023
Figure 7-50:- Global -Lunsumio Sales (US$ Million), Q1 - Q4'2023
Figure 7-51: US - Quarterly Lunsumio Sales (US$ Million), 2023
Figure 7-52: Europe - Quarterly Lunsumio Sales (US$ Million), 2023
Figure 7-53: Global - Annual Tecvayli Sales (US$ Million), 2024
Figure 7-54: Regional - US v/s ROW Sales (US$ Million), H1'2024
Figure 7-55: Global - Tecvayli Sales by Region (%), H1'2024
Figure 7-56: Global - Quarterly Tecvayli Sales (US$ Million), 2024
Figure 7-57: US - Quarterly Tecvayli Sales (US$ Million), 2024
Figure 7-58: ROW - Quarterly Tecvayli Sales (US$ Million), 2024
Figure 7-59: Global - Quarterly Tecvayli Sales (US$ Million), 2023
Figure 7-60: US - Quarterly Tecvayli Sales (US$ Million), 2023
Figure 7-61: ROW - Quarterly Tecvayli Sales (US$ Million), 2023
Figure 7-62: Global - Annual Columvi Sales (US$ Million), 2022-2024
Figure 7-63: Global - Columvi Sales by Region (US$ Million), H1'2024
Figure 7-64: Global - Columvi Sales by Region (%), H1'2024
Figure 7-65: Global - Columvi Sales by Region (US$ Million), 2023
Figure 7-66: Global - Columvi Sales by Region (%), 2023
Figure 7-67: Global - Quarterly Columvi Sales (US$ Million), 2023
Figure 7-68: US - Quarterly Columvi Sales (US$ Million), 2023
Figure 7-69: Europe - Quarterly Columvi Sales (US$ Million), 2023
Figure 7-70: Global - Annual Epkinly Sales (US$ Million), 2023-2024
Figure 7-71: Global - Quarterly Epkinly Sales (US$ Million), 2024
Figure 7-72: Global - Quarterly Epkinly Sales (US$ Million), 2023
Figure 7-73: Annual - Cadonilimab Sales (US$ Million), H2'2022 & H1'2023
Figure 8-1: Global - Multispecific Antibodies Clinical Trials by Phase (Numbers), 2024 till 2029
Figure 8-2: Global - Bispecific Antibodies Clinical Trials by Phase (Numbers), 2024 till 2029
Figure 8-3: Global - Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2024 till 2029
Figure 8-4: Global - Trispecific Antibodies Clinical Trials by Phase, 2024 till 2029
Figure 8-5: Global - Bispecific Antibodies in Clinical Trials by Country (Numbers), 2024 till 2029
Figure 8-6: Global - Tetraspecific Antibodies Clinical Trials By Company (Number Of Trials), 2024 till 2029
Figure 8-7: Global - Trispecific Antibodies Clinical Trials by Country, 2024 till 2029
Figure 8-8: Global - Bispecific Antibodies in Clinical Trials by Company (Numbers), 2024 till 2029
Figure 8-9: Global - Tetraspecific Antibodies Clinical Trials By Company (Number Of Antibodies), 2024 till 2029
Figure 8-10: Global - Trispecific Antibodies Clinical Trials by Company, 2024 till 2029
Figure 8-11: Global - Bispecific Antibodies in Clinical Trials by Indication (Numbers), 2023 till 2029
Figure 8-12: Global - Tetraspecific Antibodies Clinical Trials By Indication (Number Of Trials), 2024 till 2029
Figure 8-13: Global - Trispecific Antibodies Clinical Trials by Indication, 2024 till 2029
Figure 8-14: Global - Bispecific Antibodies in Clinical Trials by Orphan Status (Numbers), 2024 till 2029
Figure 8-15: Global - Bispecific Antibodies in Clinical Trials by Patient Segment (Numbers), 2024 till 2029
Figure 8-16: Global - Trispecific Antibodies Clinical Trials by Patient Segment, 2024 till 2029
List of Tables
Table 2-1: Estimated Total Cancer Cases, 2022 & 2040
Table 2-2: Next Generation Multispecific Antibody Market - Recent Collaborations
Table 2-3: Next Generation Multispecific Antibody Market - Recent Acquisitions
Table 2-4: Next Generation Multispecific Antibody Market - Recent Regulatory
Designations
Table 4-1: US - Multispecific Antibodies in Clinical Trials
Table 4-2: Europe - Multispecific Antibodies in Clinical Trials
Table 4-3: China - Multispecific Antibodies in Clinical Trials
Table 4-4: UK - Multispecific Antibodies in Clinical Trials
Table 4-5: Japan - Ongoing Clinical Trials for Next Generation Multispecific Antibodies
Table 4-6: Australia - Ongoing Clinical Trials for Next Generation Multispecific Antibodies
Table 4-7: South Korea - Ongoing Clinical Trials for Next Generation Multispecific Antibodies
Table 4-8: Canada - Ongoing Clinical Trials for Next Generation Multispecific Antibodies
Table 5-1: Hematological Cancers - Approved Multispecific Antibodies
Table 5-2: Hematological Malignancies - Estimated Total Cancer Cases, 2022 & 2040
Table 5-3: Solid Cancers - Approved Multispecific Antibodies
Table 5-4: Solid Cancers - Estimated Total Cancer Cases, 2022 & 2040
Table 5-5: Vabysmo - Approval Year by Indication
Table 6-1: Approved Multispecific Antibodies
Table 6-2: Blincyto - Active Patents
Table 6-3: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
Table 6-4: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 6-5: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 6-6: Rybrevant - Premedication
Table 6-7: Rybrevant - Dose Reductions for Adverse Reactions
Table 6-8: Rybrevant - Recommended Dosage Modifications for Adverse Reactions
Table 6-9: Lunsumio - Recommended Treatment Cycles
Table 6-10: Lunsumio - Recommended Premedications
Table 6-11: Lunsumio - Recommendations for Management of Cytokine Release Syndrome
Table 6-12: Tecvayli - Dosing Schedule
Table 6-13: Tecvayli - Recommended Dosage Modifications for Adverse Reactions
Table 6-14: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 6-15: Columvi - Premedications to be Administered
Table 6-16: Columvi - Recommendations for Management of Cytokine Release Syndrome
Table 6-17: Columvi - Recommended Dosage Modification for Neurologic Toxicity (Including ICANS)
Table 6-18: Columvi - Recommended Dosage Modifications for Other Adverse Reactions
Table 6-19: Epkinly - Dosage Schedule
Table 6-20: Epkinly - Recommendations for Management of Cytokine Release Syndrome
Table 6-21: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 6-22: Epkinly - Recommended Dosage Modifications for Other Adverse Reactions
Table 6-23: Talvey - Weekly Dosing Schedule
Table 6-24: Talvey - Biweekly Dosing Schedule
Table 6-25: Talvey - Recommendations for Management of CRS
Table 6-26: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 6-27: Talvey - Recommendations for Management of Neurologic Toxicity (excluding ICANS)
Table 6-28: Talvey - Recommended Dosage Modifications for Other Adverse Reactions
Table 6-29: Elrexfio - Dosing Schedule
Table 6-30: Elrexfio - Recommendations for Management of CRS
Table 6-31: Elrexfio - Recommended Dosage Modifications for Other Adverse Reactions
Table 6-32: Imdelltra - Recommended Concomitant Medications for Administration for Cycle 1
Table 6-33: Imdelltra - Recommended Dosage and Schedule of
Table 6-34: Imdelltra - Recommendations for Restarting Therapy After Dosage Delay
Table 6-35: Imdelltra - Guidelines for Grading and Dosage Modification and Management of Cytokine Release Syndrome
Table 6-36: Imdelltra - Guidelines for Management of Neurologic Toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome